Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

Semaglutide--which is marketed as Wegovy for weight-loss and Ozempic for diabetes--is now no longer listed as being in short supply in the U.S. and the FDA has told anyone distributing copies of the ...

Novo Nordisk and a popular virtual health company are making Wegovy more accessible to millions of more Americans. Hims & ...

The first round of the NFL Draft is complete, and there were plenty of surprises to kick things off. Sanders is one of the best available players remaining going into Friday, but before we get ...

Google advertising business posts solid growth Alphabet reported total revenue of $90.2bn (€79.5bn), up 12% on the year, surpassing the $89.12bn (€79.2bn) expected by analysts.

"We are deeply disappointed that the (court) misapprehended or failed to take into consideration the clear and convincing evidence that demonstrates that the manufactured supply of semaglutide is ...

The minute-long ad has been live for months, but Microsoft only just explained AI’s involvement. The minute-long ad has been live for months, but Microsoft only just explained AI’s involvement ...

70. Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy.

Sign up for the Slatest to get the most insightful analysis, criticism, and advice out there, delivered to your inbox daily. It’s no coincidence that President ...

Semaglutide injections like Ozempic have taken the world by storm—praised for their blood sugar-regulating powers and unintended weight loss effects. But while headlines focus on shrinking ...